Skip to main content

POSITION STATEMENTS

For Healthcare Professionals

November 27, 2008

Fosamax and atrial fibrillation: Osteoporosis Canada responds

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]
January 22, 2008

Osteonecrosis & Bisphosphonate position statement

Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada • Dr. Rick Adachi, Rheumatologist, McMaster University • Dr. Robert Josse, Endocrinologist, University of Toronto • Dr. […]
June 13, 2007

Osteonecrosis of the Jaw

A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]
© Osteoporosis Canada, 2025
Charitable Registration No. 89551 0931 RR 0001